Chiome Bioscience Inc. (JP:4583) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Chiome Bioscience Inc. has published promising non-clinical data for its therapeutic antibody CBA-1205, showing potential as a treatment for hepatocellular carcinoma. The study found that CBA-1205, when combined with Lenvatinib, effectively inhibited tumor growth in models, and demonstrated safety in early clinical trials. Chiome is continuing to explore CBA-1205’s potential in cancer treatment, with ongoing studies showing encouraging results.
For further insights into JP:4583 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Disney (NYSE:DIS) Cuts Stephanopoulos Pay Post-Trump Settlement
- Ford (NYSE:F) Quality Turns In Surprising Win
- Intel (NASDAQ:INTC) Narrows Down Altera Buyers
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
